VectivBio was a clinical-stage biotechnology company based in Switzerland, focused on developing innovative therapies for patients with rare and serious gastrointestinal diseases. Services provided by Niche included:
"Smaller organizations rely on the quality of final deliverables. Effective interaction and clear communication throughout any project is central to achieving that goal. Delivering that interaction is one of the differentiating factors I have experienced with Niche, not just as a vendor, but as a true partner, working closely with sponsor team members to identify best methods to plan, develop and produce a range of documentation in Phase I to Phase III scenarios."
Niche began supporting VectivBio with the apraglutide clinical programme in 2020, writing several clinical study protocols, including a protocol for their pivotal global Phase III trial. Working simultaneously on several study protocols, the Niche team were able to quickly and efficiently familiarise themselves with the details and complexities of the asset and the programme as a whole. This provided an insight which was propagated throughout the duration of the working relationship. As the programme progressed through the clinical development pipeline, services were tailored to meet the differing requirements of the regulatory pathway, including providing various study documents, laboratory manuals, protocol amendments and IB updates. The Niche team worked holistically with VectivBio. Members of the Niche Clinical Operations department worked in tandem with the Medical Writing team to share their clinical knowledge and expertise, ensuring that messaging was consistent.
In 2022, Niche was adopted as the collaborative regulatory vendor for VectivBio. The Niche team provided comprehensive support in developing the Market Application Authorisation for VectivBio’s lead product. The Niche medical writing team were integral to the strategic, temporal and clinical decision-making process, actively involved in delivering CSRs and CTD modules. Day-to-day services provided by the team included coordination, writing and editing of key documents including CTD module 2 documents, meeting summaries, timeline management, style guides and study narratives and IB updates. The team were involved in handling concurrent multidisciplinary reviews. As the submission date approached the team were intimately involved in coordinating document finalisation.
Niche played a foundational role in securing EMA approval for Strimvelis, the world's first ex vivo autologous gene.
read moreNiche provided DemeRx with end-to-end support to launch a pioneering ibogaine addiction trial, covering site.
read moreNiche partnered with Erytech Pharma to rescue and rewrite substandard clinical study reports, delivering a high-quality.
read moreWhen an Alzheimer's programme hit a wall after two negative Phase III trials, EVERSANA called on Niche to make sense of.
read moreThe clinical evidence Niche helped generate for Funxional's novel anti-inflammatory compound FX125L proved compelling.
read moreNiche prepared the full regulatory package for HOOKIPA's groundbreaking arenavirus immunotherapy platform, enabling the.
read moreWhat began as a CSR writing request grew into a broad regulatory partnership, with Niche guiding iOnctura's roginolisib.
read moreRegulatory documentation, ILAP designation and a robust clinical protocol for the Sunlight Trial — Niche helped.
read moreWorking from poor quality hard copy source materials, Niche rescued and rebuilt Thromboserin's Investigator's Brochure.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
